Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 5 clients • 11 examiners • 7 art units • 0 of 12 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
NORTON ROSE FULBRIGHT US LLP - CHMC operates in the Biotechnology & Pharmaceuticals technology area. The firm has managed 121 career applications and currently oversees 11 pending office actions. These figures indicate the firm's historical experience and its current level of engagement with the USPTO. This data provides a baseline for understanding the firm's presence in this sector.
The firm's resolved allowance rate is 85.19. On average, the firm receives 4.52 office actions per allowance. Practitioners can use this average to estimate the frequency of examiner interactions required to reach a grant for applications in this portfolio. These metrics offer an overview of the firm's prosecution results.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 1 (8%) |
| §102 only | 1 (8%) |
| §112 only | 1 (8%) |
| Multi-statute (no §101) | 7 (58%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 2 | 64.7% | +49.0% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| CORDAS, EMILY ANN | 1 | 50.8% | +57.3% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
| PATTERSON, SARAH COOPER | 1 | 55.3% | +59.5% |
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | REGLAS, GILLIAN CHELSEA | 91d overdue |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | IVICH, FERNANDO NMN | 62d |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | ROGERS, ERIC JASON | — |
| 18473619 | COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME | MONTANARI, DAVID A | — |
| 18264741 | A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK | CASH, KAILEY ELIZABETH | — |
| 18027900 | RAFT CULTURES AND METHODS OF MAKING THEREOF | MIANO, JOSEPH PAUL | — |
| 17634148 | METHODS FOR MAKING ORGANOID COMPOSITIONS | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | REGLAS, GILLIAN CHELSEA | 91d overdue |
| 17638753 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | MONTANARI, DAVID A | 34d |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | IVICH, FERNANDO NMN | 62d |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — |
| 18684587 | VASCULARIZED ORGANOIDS | CORDAS, EMILY ANN | — |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | ROGERS, ERIC JASON | — |
| 18473619 | COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME | MONTANARI, DAVID A | — |
| 18264741 | A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK | CASH, KAILEY ELIZABETH | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Children's Hospital Medical Center | 8 |
| Children's Hospital Medical Center | 1 |
| VANDERBILT UNIVERSITY | 1 |
| Riken | 1 |
| JAPAN SCIENCE AND TECHNOLOGY AGENCY | 1 |
| Art Unit | Apps |
|---|---|
| 1632 | 5 |
| 1699 | 1 |
| 1683 | 1 |
| 1631 | 1 |
| 1678 | 1 |
| 1675 | 1 |
| 1634 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18847004 | DELIVERY METHODS USING PLATELETS | Children'S Hospital Medical Center | MARVICH, MARIA | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 | |
| 18684587 | VASCULARIZED ORGANOIDS | Children’S Hospital Medical Center | CORDAS, EMILY ANN | 1632 | §112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | Children'S Hospital Medical Center | ROGERS, ERIC JASON | 1699 | §102§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18473619 | COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME | Children'S Hospital Medical Center | MONTANARI, DAVID A | 1632 | §101§103Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18264741 | A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK | VANDERBILT UNIVERSITY | CASH, KAILEY ELIZABETH | 1683 | §102§103 | Final Rejection | — | Pending | Aug 08, 2023 |
| 18027900 | RAFT CULTURES AND METHODS OF MAKING THEREOF | Children'S Hospital Medical Center | MIANO, JOSEPH PAUL | 1631 | §103§112 | Final Rejection | — | Pending | Mar 22, 2023 |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | Children'S Hospital Medical Center | IVICH, FERNANDO NMN | 1678 | §103§112Other | Non-Final OA | 62d | Pending | Jan 31, 2023 |
| 17638753 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | Riken | MONTANARI, DAVID A | 1632 | §102 | Final Rejection | 34d | Pending | Feb 25, 2022 |
| 17634148 | METHODS FOR MAKING ORGANOID COMPOSITIONS | Children'S Hospital Medical Center | BEHARRY, ZANNA MARIA | 1632 | §101§103§112Other | Non-Final OA | — | Pending | Feb 09, 2022 |
| 17617165 | RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N | Children'S Hospital Medical Center | PATTERSON, SARAH COOPER | 1675 | §103§112 | Non-Final OA | — | Pending | Dec 07, 2021 |
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | Children'S Hospital Medical Center | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | 91d overdue | Pending | Jul 09, 2021 |
| 16346188 | LIVER ORGANOID COMPOSITIONS AND METHODS OF MAKING AND USING SAME | Japan Science And Technology Agency | CONNORS, ALEXANDRA F | 1634 | §103Other | Non-Final OA | — | Pending | Apr 30, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial